Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

Blood (2021) 138 (21): 2142–2148.

https://doi.org/10.1182/blood.2020010402

Published: 2021

Includes: Supplemental data

Journal Articles

High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia

Blood (2021) 138 (Supplement 1): 2526.

https://doi.org/10.1182/blood-2021-145440

Published: 2021

Journal Articles

Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF)

Nicolas Gauthier, MD, Juliette Soret-Dulphy, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Nathalie Parquet, MD, Jean-Marc Zini, Delphine Rea, MDPhD, Emmanuel Raffoux, MD, Bruno Cassinat, PharmD, PhD, Stephane Giraudier, MD PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-141260

Published: 2020

Journal Articles

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Clemence Marcault, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-136177

Published: 2020

Journal Articles

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, MD, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141296

Published: 2020

Journal Articles

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Gabriel Levy, Serge Carillo, Benjamin Papoular, Bruno Cassinat, Jean-Marc Zini, Emilie Leroy, Leila N. Varghese, Ilyas Chachoua, Jean-Philippe Defour, Steven O. Smith, Stefan N. Constantinescu

Blood (2020) 135 (12): 948–953.

https://doi.org/10.1182/blood.2019003240

Published: 2020

Includes: Supplemental data

Journal Articles

Clinical Spectrum, Long-Term Outcomes and Predictors of Relapse after Imatinib Discontinuation in FIP1L1-Pdgfra-Associated Chronic Eosinophilic Leukemia: Data from 150 Patients

Blood (2019) 134 (Supplement_1): 840.

https://doi.org/10.1182/blood-2019-130009

Published: 2019

Journal Articles

Retrospective Analysis of 56 Cases of Transformed Waldenström Macroglobulinemia. a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Eric Durot, MD, Cecile Tomowiak, MD, Anne-Sophie Michallet, MD, Jehan Dupuis, MD, Stephane Lepretre, Elise Toussaint, MD, Sophie Godet, Fatiha Merabet, Eric W Van Den Neste, MD PhD, Sarah Ivanoff, Jean-Marc Zini, MD PhD, Caroline Régny, Aurore Perrot, MD, Lukshe Kanagaratnam, Pierre Morel, MD, Veronique Leblond, Alain Delmer, MD PhD

Blood (2016) 128 (22): 2982.

https://doi.org/10.1182/blood.V128.22.2982.2982

Published: 2016

Journal Articles

Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain

Annalisa Andreoli, MD, Emmanuelle Verger, PhD, Marie Robin, MD, PhD, Emmanuel Raffoux, Jean-Marc Zini, MD, PhD, Philippe Rousselot, MD, PhD, Gérard Socié, MD, PhD, Delphine Rea, MD, PhD, Nathalie Parquet, MD, Stephane Giraudier, MD, PhD, Christine Chomienne, MD, PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD, PhD

Blood (2013) 122 (21): 1591.

https://doi.org/10.1182/blood.V122.21.1591.1591

Published: 2013

Journal Articles

Salvage Therapies in Patients with High-Risk Relapse After Fludarabine, Cyclophosphamide, Rituximab (FCR) for Chronic Lymphocytic Leukemia: The French CLL Intergroup Experience

Luc-Matthieu Fornecker, MD, Therese Aurran-Schleinitz, Anne-Sophie Michallet, MD, PhD, Bruno Cazin, MD, Jehan Dupuis, MD, Romain Guieze, MD, Marie-Sarah Dilhuydy, MD, Jean-Marc Zini, MD, PhD, Cécile Tomowiak, MD, Stéphane Leprêtre, MD, Florence Cymbalista, MD, PhD, Annie Brion, MD, Pierre Feugier, MD, PhD, Veronique Leblond, Loic Ysebaert, MD PhD

Blood (2012) 120 (21): 1796.

https://doi.org/10.1182/blood.V120.21.1796.1796

Published: 2012

Journal Articles

18 F-FLT Positron Emission Tomography (PET)/CT Imaging in Myelofibrosis: A Non Invasive Method to Assess Bone Marrow Function and Extramedullary Hematopoiesis

Annalisa Andreoli, MD, Laetitia Vercellino, Mathieu-John Ouvrier, Emmanuelle Barré, Bruno Cassinat, PharmD, PhD, Virginie de Beco, Jean-Marc Zini, MD, PhD, Pascal Merlet, MD, Christine Dosquet, MD, Christine Chomienne, MD, PhD, Marie-Elisabeth Toubert, Jean-Jacques Kiladjian, MD, PhD

Blood (2012) 120 (21): 1741.

https://doi.org/10.1182/blood.V120.21.1741.1741

Published: 2012

Journal Articles

Complete Hematological, Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon α-2a (peg-IFNα-2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 Trial

Pascal Turlure, MD, Nathalie Cambier, MD, Murielle Roussel, Sylvia Bellucci, MD, PhD, Jean-Marc Zini, MD, PhD, Jean-Didier Rain, MD, Philippe Rousselot, MD, PhD, William Vainchenker, MD, PhD, Lina Abdelkader, Kamel Ghomari, Jean-Luc Dutel, Yasmine Chait, Sylvie Chevret, Christine Chomienne, MD, PhD, Bruno Cassinat, PharmD, Jean-Jacques Kiladjian, MD, PhD

Blood (2011) 118 (21): 280.

https://doi.org/10.1182/blood.V118.21.280.280

Published: 2011

Journal Articles

Intensive Chemotherapy Followed by Hematopoietic Stem Cell Rescue for Refractory or Recurrent Primary Central Nervous System (PCNSL) or Intra Ocular Lymphoma (IOL). Results of a Multicentric Phase II Study.

Carole Soussain, MD, Khe Hoang-Xuan, MD, Luc Taillandier, MD, Olivier Casasnovas, MD, Brigitte Dupriez, MD, Anne-Laure Taksin, MD, Bertrand Souleau, MD, Brigitte Kolb, MD, Arnaud Jaccard, MD, Jean-Marc Zini, MD, Sylvain Choquet, MD, Francis Witz, MD, Maud Janvier, MD, Veronique Leblond, MD

Blood (2006) 108 (11): 402.

https://doi.org/10.1182/blood.V108.11.402.402

Published: 2006

Journal Articles

L-Asparaginase in the Treatment of Relapsing Nasal/Nasal Type NK-T-Cell Lymphoma.

Arnaud Jaccard, MD, Felipe Suarez, MD, Jean-Marc Zini, MD, Pascal Turlure, MD, Franck Trimoreau, MD, Barbara Petit, MD, Dominique Bordessoule, MD, Olivier Hermine, MD

Blood (2004) 104 (11): 4598.

https://doi.org/10.1182/blood.V104.11.4598.4598

Published: 2004

Journal Articles

Erythroblastic Synartesis: An Auto-immune Dyserythropoiesis

Elisabeth M. Cramer, Isabel Garcia, Jean-Marc Massé, Jean-Marc Zini, Patrick Lambin, Eric Oksenhendler, Fadila Souni, Mark Smith, Georges Flandrin, Janine Breton-Gorius, Gérard Tobelem, Nicole Casadevall

Blood (1999) 94 (11): 3683–3693.

https://doi.org/10.1182/blood.V94.11.3683

Published: 1999

NARROW

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia

Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF)

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Clinical Spectrum, Long-Term Outcomes and Predictors of Relapse after Imatinib Discontinuation in FIP1L1-Pdgfra-Associated Chronic Eosinophilic Leukemia: Data from 150 Patients

Retrospective Analysis of 56 Cases of Transformed Waldenström Macroglobulinemia. a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain

Salvage Therapies in Patients with High-Risk Relapse After Fludarabine, Cyclophosphamide, Rituximab (FCR) for Chronic Lymphocytic Leukemia: The French CLL Intergroup Experience

18 F-FLT Positron Emission Tomography (PET)/CT Imaging in Myelofibrosis: A Non Invasive Method to Assess Bone Marrow Function and Extramedullary Hematopoiesis

Complete Hematological, Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon α-2a (peg-IFNα-2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 Trial

Intensive Chemotherapy Followed by Hematopoietic Stem Cell Rescue for Refractory or Recurrent Primary Central Nervous System (PCNSL) or Intra Ocular Lymphoma (IOL). Results of a Multicentric Phase II Study.

L-Asparaginase in the Treatment of Relapsing Nasal/Nasal Type NK-T-Cell Lymphoma.

Erythroblastic Synartesis: An Auto-immune Dyserythropoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only